What's new

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 20, Status: Authorised

Mar 26, 2025 - 11:53
 0
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 20, Status: Authorised
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 20, Status: Authorised
Read More

Tags:

Previous Article

Nissan and INFINITI outline bold new products and next-generation technologies

Next Article

India eyes global cotton leadership through yield & quality boosts

Related Posts

Human medicines European public assessment report (EPAR): mResvia, Single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Date of authorisation: 14/10/1998, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025  0